Key Record Dates
| ClinicalTrials.gov Identifier: | NCT01532089 |
|---|---|
| Brief Title: | Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations |
| First Submitted : | February 7, 2012 |
| First Submitted that Met QC Criteria : | February 9, 2012 |
| First Posted : | February 14, 2012 (Estimate) |
| Results First Submitted : | December 9, 2019 |
| Results First Submitted that Met QC Criteria : | December 11, 2019 |
| Results First Posted : | December 26, 2019 |
| Last Update Submitted that Met QC Criteria : | September 16, 2020 |
| Last Update Posted : | October 6, 2020 |